• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎的肾脏受累:文献综述

Renal Involvement in COVID-19: A Review of the Literature.

作者信息

Migliaccio Marco Giuseppe, Di Mauro Marco, Ricciolino Riccardo, Spiniello Giorgio, Carfora Vincenzo, Verde Nicoletta, Mottola Filiberto Fausto, Coppola Nicola

机构信息

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Department of Mental Health and Public Medicine, Infectious Diseases Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

Infect Drug Resist. 2021 Mar 5;14:895-903. doi: 10.2147/IDR.S288869. eCollection 2021.

DOI:10.2147/IDR.S288869
PMID:33707958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7943324/
Abstract

Kidney injury may be a severe complication of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and contributes to worsen the prognosis. Various pathophysiological mechanisms can contribute to organ damage and impair renal function, proving the complexity of the virus activity and the resulting immunity response. We summarized the evidence of the literature on the prevalence of kidney involvement, on the pathogenic pathways and on its management.

摘要

肾损伤可能是严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的一种严重并发症,并会导致预后恶化。多种病理生理机制可导致器官损伤并损害肾功能,这证明了病毒活性及其引发的免疫反应的复杂性。我们总结了关于肾脏受累的患病率、致病途径及其管理的文献证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ac/7943324/e6b5e4a4553d/IDR-14-895-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ac/7943324/c56e298aeccd/IDR-14-895-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ac/7943324/e6b5e4a4553d/IDR-14-895-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ac/7943324/c56e298aeccd/IDR-14-895-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ac/7943324/e6b5e4a4553d/IDR-14-895-g0002.jpg

相似文献

1
Renal Involvement in COVID-19: A Review of the Literature.新型冠状病毒肺炎的肾脏受累:文献综述
Infect Drug Resist. 2021 Mar 5;14:895-903. doi: 10.2147/IDR.S288869. eCollection 2021.
2
Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review.SARS-CoV-2 感染致肾损伤机制的文献研究
Front Cell Infect Microbiol. 2022 Jun 14;12:838213. doi: 10.3389/fcimb.2022.838213. eCollection 2022.
3
Renal Involvement in Pediatric Patients with COVID-19: An Up-to-date Review.新冠病毒感染儿科患者的肾脏受累:最新综述
Curr Pediatr Rev. 2021;17(4):253-263. doi: 10.2174/1573396317666210924121550.
4
Coronavirus Disease 2019: Coronaviruses and Kidney Injury.2019 年冠状病毒病:冠状病毒与肾脏损伤。
J Urol. 2020 Nov;204(5):918-925. doi: 10.1097/JU.0000000000001289. Epub 2020 Jul 17.
5
COVID-19 and Acute Kidney Injury - Direct and Indirect Pathophysiological Mechanisms Underlying Lesion Development.新型冠状病毒肺炎与急性肾损伤——损伤发生的直接和间接病理生理机制
An Acad Bras Cienc. 2022 Dec 5;94(suppl 3):e20211501. doi: 10.1590/0001-3765202220211501. eCollection 2022.
6
A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results.Covid-19 与急性肾损伤:从病理生理学到临床结果的综述。
J Bras Nefrol. 2021 Oct-Dec;43(4):551-571. doi: 10.1590/2175-8239-JBN-2020-0204.
7
Myocardial injury and COVID-19: Possible mechanisms.心肌损伤与 COVID-19:可能的机制。
Life Sci. 2020 Jul 15;253:117723. doi: 10.1016/j.lfs.2020.117723. Epub 2020 Apr 28.
8
Pathogenesis and histological changes of nephropathy associated with COVID-19.新型冠状病毒肺炎相关肾病的发病机制及组织学变化
J Med Virol. 2023 Jan;95(1):e28311. doi: 10.1002/jmv.28311.
9
Highly pathogenic coronaviruses and the kidney.高致病性冠状病毒与肾脏。
Biomed Pharmacother. 2022 Dec;156:113807. doi: 10.1016/j.biopha.2022.113807. Epub 2022 Oct 11.
10
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.COVID-19 与肾脏疾病:肾癌中的分子决定因素和临床意义。
Eur Urol Focus. 2020 Sep 15;6(5):1086-1096. doi: 10.1016/j.euf.2020.06.002. Epub 2020 Jun 9.

引用本文的文献

1
Transcriptome and machine learning analysis of the impact of COVID-19 on mitochondria and multiorgan damage.COVID-19 对线粒体和多器官损伤影响的转录组学和机器学习分析。
PLoS One. 2024 Jan 31;19(1):e0297664. doi: 10.1371/journal.pone.0297664. eCollection 2024.
2
Metabolism of Polyamines and Kidney Disease: A Promising Therapeutic Target.多胺代谢与肾脏疾病:一个有前景的治疗靶点。
Kidney Dis (Basel). 2023 Aug 10;9(6):469-484. doi: 10.1159/000533296. eCollection 2023 Dec.
3
Factors associated with acute kidney injury (AKI) and mortality in COVID-19 patients in a Sub-Saharan African intensive care unit: a single-center prospective study.

本文引用的文献

1
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.在危重症 COVID-19 患者中抑制 CCR5 可减少炎症细胞因子,增加 CD8 T 细胞,并在第 14 天降低血浆中的 SARS-CoV2 RNA。
Int J Infect Dis. 2021 Feb;103:25-32. doi: 10.1016/j.ijid.2020.10.101. Epub 2020 Nov 10.
2
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).恢复期血浆治疗印度成人中度 COVID-19 的管理:开放标签 II 期多中心随机对照试验(PLACID 试验)。
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
3
撒哈拉以南非洲重症监护病房 COVID-19 患者急性肾损伤(AKI)和死亡率的相关因素:一项单中心前瞻性研究。
Ren Fail. 2023;45(2):2263583. doi: 10.1080/0886022X.2023.2263583. Epub 2023 Oct 23.
4
Prognostic Value of Creatinine Levels at Admission on Disease Progression and Mortality in Patients with COVID-19-An Observational Retrospective Study.入院时肌酐水平对COVID-19患者疾病进展和死亡率的预后价值——一项观察性回顾性研究
Pathogens. 2023 Jul 25;12(8):973. doi: 10.3390/pathogens12080973.
5
Association between the severity of periodontitis, COVID-19, C-reactive protein and interleukin-6 levels in hospitalized patients: a case‒control study.牙周炎严重程度与住院患者 COVID-19、C 反应蛋白和白细胞介素 6 水平的相关性:一项病例对照研究。
BMC Oral Health. 2023 Aug 11;23(1):556. doi: 10.1186/s12903-023-03270-x.
6
Hematologic tests and their association with the severity of COVID-19 and periodontitis in hospitalized patients: a case-control study.血液学检查及其与住院患者 COVID-19 严重程度和牙周炎的关系:一项病例对照研究。
BMC Oral Health. 2023 Jul 11;23(1):473. doi: 10.1186/s12903-023-03208-3.
7
Relationship between positive end-expiratory pressure levels, central venous pressure, systemic inflammation and acute renal failure in critically ill ventilated COVID-19 patients: a monocenter retrospective study in France.危重症COVID-19通气患者呼气末正压水平、中心静脉压、全身炎症与急性肾衰竭之间的关系:法国一项单中心回顾性研究
Acute Crit Care. 2023 May;38(2):172-181. doi: 10.4266/acc.2022.01494. Epub 2023 May 25.
8
Post COVID-19 syndrome and new onset diseases: a prospective observational study.新冠后综合征与新发疾病:一项前瞻性观察研究
Singapore Med J. 2025 Jul 1;66(7):354-361. doi: 10.4103/singaporemedj.SMJ-2022-055. Epub 2023 Apr 7.
9
Cystatin-c May Indicate Subclinical Renal Involvement, While Orosomucoid Is Associated with Fatigue in Patients with Long-COVID Syndrome.胱抑素 C 可能提示亚临床肾脏受累,而血清类黏蛋白与长期新冠综合征患者的疲劳相关。
J Pers Med. 2023 Feb 19;13(2):371. doi: 10.3390/jpm13020371.
10
Impact of concomitant COVID-19 on the outcome of patients with acute myocardial infarction undergoing coronary artery angiography.新型冠状病毒肺炎(COVID-19)合并感染对接受冠状动脉造影的急性心肌梗死患者预后的影响。
Front Cardiovasc Med. 2022 Sep 22;9:917250. doi: 10.3389/fcvm.2022.917250. eCollection 2022.
Convalescent plasma is ineffective for covid-19.
康复期血浆对新冠病毒肺炎无效。
BMJ. 2020 Oct 22;371:m4072. doi: 10.1136/bmj.m4072.
4
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab.接受同情使用 Leronlimab 的 2019 年冠状病毒病患者的临床特征和结局。
Clin Infect Dis. 2021 Dec 6;73(11):e4082-e4089. doi: 10.1093/cid/ciaa1583.
5
COVID-19 infection in kidney transplant recipients at the epicenter of pandemics.COVID-19 感染在疫情中心的肾移植受者中。
Kidney Int. 2020 Dec;98(6):1559-1567. doi: 10.1016/j.kint.2020.10.004. Epub 2020 Oct 16.
6
Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor?新冠病毒肺炎中的心血管系统:仅仅是旁观者还是主角?
Life (Basel). 2020 Aug 27;10(9):165. doi: 10.3390/life10090165.
7
CKD is a key risk factor for COVID-19 mortality.CKD 是 COVID-19 死亡的一个关键风险因素。
Nat Rev Nephrol. 2020 Dec;16(12):705-706. doi: 10.1038/s41581-020-00349-4.
8
Efficacy of Remdesivir in COVID-19.瑞德西韦治疗新型冠状病毒肺炎的疗效
JAMA. 2020 Sep 15;324(11):1041-1042. doi: 10.1001/jama.2020.16337.
9
Anticoagulant treatment in COVID-19: a narrative review.新型冠状病毒肺炎的抗凝治疗:叙述性综述。
J Thromb Thrombolysis. 2021 Apr;51(3):642-648. doi: 10.1007/s11239-020-02242-0.
10
Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review.新型冠状病毒肺炎实验室诊断的现状:一篇综述
Infect Drug Resist. 2020 Aug 3;13:2657-2665. doi: 10.2147/IDR.S264020. eCollection 2020.